Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 4
1967 2
1968 5
1969 5
1970 8
1971 14
1972 10
1973 5
1974 10
1975 5
1976 7
1977 6
1978 11
1979 8
1980 18
1981 8
1982 9
1983 18
1984 13
1985 19
1986 27
1987 24
1988 32
1989 28
1990 33
1991 42
1992 28
1993 40
1994 56
1995 63
1996 65
1997 48
1998 59
1999 57
2000 79
2001 89
2002 78
2003 76
2004 93
2005 82
2006 72
2007 60
2008 58
2009 43
2010 41
2011 33
2012 38
2013 31
2014 36
2015 22
2016 38
2017 34
2018 30
2019 18
2020 16
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

1,753 results
Results by year
Filters applied: . Clear all
Page 1
17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
Blackwell SC, Gyamfi-Bannerman C, Biggio JR Jr, Chauhan SP, Hughes BL, Louis JM, Manuck TA, Miller HS, Das AF, Saade GR, Nielsen P, Baker J, Yuzko OM, Reznichenko GI, Reznichenko NY, Pekarev O, Tatarova N, Gudeman J, Birch R, Jozwiakowski MJ, Duncan M, Williams L, Krop J. Blackwell SC, et al. Am J Perinatol. 2020 Jan;37(2):127-136. doi: 10.1055/s-0039-3400227. Epub 2019 Oct 25. Am J Perinatol. 2020. PMID: 31652479 Free article. Clinical Trial.
BACKGROUND: Women with a history of spontaneous preterm birth (SPTB) are at a significantly increased risk for recurrent preterm birth (PTB). To date, only one large U.S. clinical trial comparing 17-OHPC (17-alpha-hydroxyprogesterone caproate or "17P") …
BACKGROUND: Women with a history of spontaneous preterm birth (SPTB) are at a significantly increased risk for recurrent preterm birth (PTB) …
Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, Spong CY, Hauth JC, Miodovnik M, Varner MW, Leveno KJ, Caritis SN, Iams JD, Wapner RJ, Conway D, O'Sullivan MJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Meis PJ, et al. N Engl J Med. 2003 Jun 12;348(24):2379-85. doi: 10.1056/NEJMoa035140. N Engl J Med. 2003. PMID: 12802023 Free article. Clinical Trial.
BACKGROUND: Women who have had a spontaneous preterm delivery are at greatly increased risk for preterm delivery in subsequent pregnancies. The results of several small trials have suggested that 17 alpha-hydroxyprogesterone caproate (17P) may reduce the risk …
BACKGROUND: Women who have had a spontaneous preterm delivery are at greatly increased risk for preterm delivery in subsequent pregnancies. …
A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
El-Maouche D, Merke DP, Vogiatzi MG, Chang AY, Turcu AF, Joyal EG, Lin VH, Weintraub L, Plaunt MR, Mohideen P, Auchus RJ. El-Maouche D, et al. J Clin Endocrinol Metab. 2020 Aug 1;105(8):2771-8. doi: 10.1210/clinem/dgaa381. J Clin Endocrinol Metab. 2020. PMID: 32589738 Free PMC article. Clinical Trial.
Nevanimibe hydrochloride (ATR-101), which selectively inhibits adrenal cortex function, might reduce androgen excess independent of ACTH and thus allow for lower glucocorticoid dosing in CAH. 17-hydroxyprogesterone (17-OHP) and androstenedione are CAH biomark …
Nevanimibe hydrochloride (ATR-101), which selectively inhibits adrenal cortex function, might reduce androgen excess independent of ACTH and …
Adherence rates and outcomes for 17-hydroxyprogesterone caproate use in women with a previous history of preterm birth.
Edwards AM, Lowry SA, Mikovich S, Forinash AB, Babbar S. Edwards AM, et al. Am J Obstet Gynecol MFM. 2020 Aug;2(3):100166. doi: 10.1016/j.ajogmf.2020.100166. Epub 2020 Jun 25. Am J Obstet Gynecol MFM. 2020. PMID: 33345885 Clinical Trial.
Women receiving 17-hydroxyprogesterone caproate injections outside of the clinic were excluded. ...Further studies are needed to assess the outpatient administration and benefit of 17-hydroxyprogesterone caproate therapy....
Women receiving 17-hydroxyprogesterone caproate injections outside of the clinic were excluded. ...Further studies are needed …
Effect of Lepidium meyenii (Maca), a root with aphrodisiac and fertility-enhancing properties, on serum reproductive hormone levels in adult healthy men.
Gonzales GF, Córdova A, Vega K, Chung A, Villena A, Góñez C. Gonzales GF, et al. J Endocrinol. 2003 Jan;176(1):163-8. doi: 10.1677/joe.0.1760163. J Endocrinol. 2003. PMID: 12525260 Clinical Trial.
Serum levels of luteinizing hormone, follicle-stimulating hormone, prolactin, 17-alpha hydroxyprogesterone, testosterone and 17-beta estradiol were measured before and at 2, 4, 8 and 12 weeks of treatment with placebo or Maca (1.5 g or 3.0 g per day). …
Serum levels of luteinizing hormone, follicle-stimulating hormone, prolactin, 17-alpha hydroxyprogesterone, testosteron …
Progesterone receptor polymorphisms and clinical response to 17-alpha-hydroxyprogesterone caproate.
Manuck TA, Lai Y, Meis PJ, Dombrowski MP, Sibai B, Spong CY, Rouse DJ, Durnwald CP, Caritis SN, Wapner RJ, Mercer BM, Ramin SM. Manuck TA, et al. Am J Obstet Gynecol. 2011 Aug;205(2):135.e1-9. doi: 10.1016/j.ajog.2011.03.048. Epub 2011 Apr 8. Am J Obstet Gynecol. 2011. PMID: 21600550 Free PMC article. Clinical Trial.
OBJECTIVE: Seventeen-alpha-hydroxyprogesterone caproate (17-OHPC) reduces recurrent preterm birth (PTB). We hypothesized that single nucleotide polymorphisms in the human progesterone receptor (PGR) affect response to 17-OHPC in the prevention of recur …
OBJECTIVE: Seventeen-alpha-hydroxyprogesterone caproate (17-OHPC) reduces recurrent preterm birth (PTB). We hypothesize …
17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial.
Combs CA, Garite T, Maurel K, Das A, Porto M; Obstetrix Collaborative Research Network. Combs CA, et al. Am J Obstet Gynecol. 2011 Mar;204(3):221.e1-8. doi: 10.1016/j.ajog.2010.12.042. Am J Obstet Gynecol. 2011. PMID: 21376161 Clinical Trial.
OBJECTIVE: We sought to determine whether prophylactic treatment with 17-alpha-hydroxyprogesterone caproate (17Pc) in twin pregnancy will reduce neonatal morbidity (primary outcome) by prolonging pregnancy (secondary outcome). ...
OBJECTIVE: We sought to determine whether prophylactic treatment with 17-alpha-hydroxyprogesterone caproate (17Pc) in t …
Estrus induction and fertility rates in response to exogenous hormonal administration in postpartum anestrous and subestrus bovines and buffaloes.
Honparkhe M, Singh J, Dadarwal D, Dhaliwal GS, Kumar A. Honparkhe M, et al. J Vet Med Sci. 2008 Dec;70(12):1327-31. doi: 10.1292/jvms.70.1327. J Vet Med Sci. 2008. PMID: 19122399 Free article. Clinical Trial.
True anestrous animals (Gp Ia) were treated with 3 injections of hydroxyprogesterone caproate (750 mg, i.m.) at 72-hr intervals followed by injection of equine chorionic gonadotropin (eCG; 750 I.U., i.m.) 72 hr after the last progesterone injection. ...
True anestrous animals (Gp Ia) were treated with 3 injections of hydroxyprogesterone caproate (750 mg, i.m.) at 72-hr intervals follo …
Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.
Caritis SN, Venkataramanan R, Thom E, Harper M, Klebanoff MA, Sorokin Y, Thorp JM Jr, Varner MW, Wapner RJ, Iams JD, Carpenter MW, Grobman WA, Mercer BM, Sciscione A, Rouse DJ, Ramin S; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network and Obstetric-Fetal Pharmacology Research Units Network. Caritis SN, et al. Am J Obstet Gynecol. 2014 Feb;210(2):128.e1-6. doi: 10.1016/j.ajog.2013.10.008. Epub 2013 Oct 7. Am J Obstet Gynecol. 2014. PMID: 24113254 Free PMC article. Clinical Trial.
Plasma from 315 consenting women was analyzed for 17-alpha hydroxyprogesterone caproate concentration. RESULTS: There were no differences between placebo and omega-3 supplemented groups in demographic variables, outcomes or in mean 17-alpha h
Plasma from 315 consenting women was analyzed for 17-alpha hydroxyprogesterone caproate concentration. RESULTS: There w …
Adrenal morphology and associated comorbidities in congenital adrenal hyperplasia.
El-Maouche D, Hannah-Shmouni F, Mallappa A, Hargreaves CJ, Avila NA, Merke DP. El-Maouche D, et al. Clin Endocrinol (Oxf). 2019 Aug;91(2):247-255. doi: 10.1111/cen.13996. Epub 2019 May 7. Clin Endocrinol (Oxf). 2019. PMID: 31001843 Free PMC article. Clinical Trial.
RESULTS: Over one-third of the cohort was obese. 53% had elevated 17-OH-progesterone or androstenedione; and 60% had adrenal hyperplasia. ...
RESULTS: Over one-third of the cohort was obese. 53% had elevated 17-OH-progesterone or androstenedione; and 60% had adrenal hyperpla …
1,753 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page